Wuttisak Groups direction is to indicating to be a beauty and wellness Asias leader

Food and Healthcare Press Releases Friday June 23, 2017 14:15
Bangkok--23 Jun--pr boom
Wuttisak Group's direction is to indicating to be a beauty and wellness Asia's leader, expanding by franchise system and there are now morethan 50 prospect franchise units.

Wuttisak Group makes the business clearly defined and bring out the strength of his number one in health and beauty with 15 years of experiences. The Franchise Business Model is going to be expanding tolocal and overseas and there will be more 50 franchise units which will be invested by the people who interested in. Moreover, there is That ' so, a global innovation from Italy, which will makeWuttisak to be the Asian beauty and wellness leader.

Mr. AutthawutJingtaisong, Chief Executive Officer of Wuttisak Clinic Inter Group Co., Ltd (Wuttisak Group), has indicated that nowadays, the beauty industry's businesses are growing continuously in Asia and global level. The market value is250,000 million baht and more than 10% growth per year. Theses show that there is more demand from customers and the beauty industry is highly competitive.

The core value of Wuttisak Group is "To be the Leader in Beauty Wellness in Asia"which is driven by 5 strategies, 1.Innovation in Beauty Medical Center 2.Innovation in Beauty Wellness Center 3.Franchise Business Model 4.World-Class Beauty Wellness Academyand 5.Partnership with Strategic Partners. Itcan assure that the 5 strategies would make Wuttisak to be the number one in health and beauty within Thailand and be a Global Brand and can make 10% profit growth or 2,000 million baht this year.

Mr. AutthawutJingtaisong added that franchise is one of the business expansion system that works well and was accepted by world standard. It aims to build the strong relationships and networks swiftly and professionally. Wuttisak is a success business which is efficient and ready to expand, whether it be, Branding which was accepted by Asian and global level, Know Howwhich is continuously develop more than 15 years and Franchise Team that gained more franchise experiences and make many franchise succeeded.

Wuttisak Group has a flexible Franchise Business Models in order to meet the investor's needs as following;
1.Wuttisak Clinic: 120-150 square meters with Investmentof 6-8 million baht. There will be a medical specialists who will provide all consultation, derma treatment beauty surgery.

2.Wuttisak Beauty: 80-100 square meters with Investmentof 5-7million baht. This will be an health and beauty innovation center providing one stop service from head to toe and bring That ' so's product from Italy,Global Beauty Innovation, there.

3. Wuttisak Cosmetic Shop: 50-70 square meters with Investmentof 1.5-2.5 million baht. This would be the retail shop of Beauty & Cosmetic products of Wuttisak and partnership's brands. By supporting from banks for loan, the people who interested in franchise business will be more easy to obtain franchise's right and now there are 50 prospect franchisors.

Apart from the above mentioned, another important thing is that Wuttisak has a full Franchise Support given to Franchisee in order to make it convenient in management and get a high satisfaction such as supporting from the beginning, management, front operation controlled with a new innovation to confirm that it would be good and correct things to do. Besides, Wuttisak will select and provide the best quality products and innovation in order to meet the customer's needs including providing support in marketing and advertising to maintain the royal customers and make new customers. Furthermore, the medical knowledge, service, sales and marketing will be passed on from W Academy Institute to make sure that Franchisees will operate franchise unit professionally and confidently.

Mr. AuttawutJingtaisong added that the expansion will be achieved within 3years. there will be 300 units dividedby 150 beauty clinics, 50 beauty centers and 100 retail shops.There are 120 Wuttisak units within Thailand and the planning of international road show including in Cambodia, Laos, Myanmar, Philippines, Indonesia, and Singapore.

For any further information required, please contactWuttisak Clinic Inter Group Co., Ltd CALL CENTER : 02-834-6666andhttps://www.wuttisakclinic.com/
For Press, if you have more information required, please contact Public Relations, KhunPanya, Tel. 087-055-2756 and KhunManassawin Tel. 081-438-7353

Latest Press Release

New Research Shows Significant Benefits for COPD Patients in the Home Using Fisher Paykel Healthcare#s myAirvo

Fisher & Paykel Healthcare Corporation Limited announced today that new research has been published in the International Journal of COPD which demonstrates significant benefits of nasal high flow therapy for COPD* patients using Fisher & Paykel...

Swift Biosciences Launches Accel-Amplicon Plus Cancer Panels for Precision Medicine Initiatives

- New targeted sequencing workflow combines pre-validated content with easy customization and new analysis tools to accelerate variant discovery and screening Swift Biosciences today announced the commercial release of its Accel-Amplicon Plus(TM) Cancer...

Sotera Health LLC announces intent to sell Nordion#s Medical Isotopes segment to BWXT

Sotera Health committed to Safeguarding Global Health(TM) with Nordion's increased focus on global gamma technologies business Sotera Health LLC, the world's leading, fully integrated protector of global health, today announced that it has entered into...

On World Hemophilia Day 2018, Shire Unites Communities in Asia Pacific and Advocates for #Principles of Care#

Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotech leader in rare diseases, is marking World Hemophilia Day ( https://www.wfh.org/en/whd ) to drive greater awareness of hemophilia in Asia Pacific (APAC) and improve standards of care for people living...

Menarini Ricerche to Present the Most Recent Pre-clinical Data About the PI3K Inhibitor MEN1611 at the AACR Annual Meeting 2018

Menarini Ricerche will present on the latest preclinical studies of its phosphatidylinositol 3-kinase (PI3K) class I inhibitor MEN1611, in development for solid tumors, at the AACR Annual Meeting 2018, which will take place on April 14-18, 2018, in...

Related Topics